Faculty profile

Waqqas Afif

ResearcherMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Waqqas Afif

Researcher

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
56 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

113

Publications

495

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Comparative Effectiveness And Safety Confounding Bias Exposure Measurement Errors Pharmacoepidemiology Prospective Studies Statistical Modelling

Latest papers

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
The American journal of gastroenterology · 2026
An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response.
Journal of the Canadian Association of Gastroenterology · 2026 · senior author
Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.
International archives of allergy and immunology · 2026

All 113 publications

Latest funding

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat
CIHR · 2026 · Co-investigator
$1,005,976
Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).
CIHR · 2023 · Co-investigator
$5,222,039
Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).
CIHR · 2023 · Co-investigator
$1,305,510

All 6 grants and awards

113 publications.

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

Lichtenstein GR, Allegretti JR, Rubin DT, Magro F, Bressler B, Panés J, Afif W, Samaan MA, Ye BD, Yarandi S, Germinaro M, Shipitofsky N, Miao Y, Zhang H, Dignass A, Sands BE, Hisamatsu T, Peyrin-Biroulet L

The American journal of gastroenterology2026

DOI: 10.14309/ajg.0000000000004041 PMID: 42065421

An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response.

De Marco D, McHugh K, Plamondon S, Rioux LC, Steinhart AH, Horvat M, Afif W

Journal of the Canadian Association of Gastroenterology2026Senior author

DOI: 10.1093/jcag/gwag002 PMID: 42244850

Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.

Khalaf R, Ton That A, Tardio N, Afif W, Schneider R, Ben-Shoshan M

International archives of allergy and immunology2026

DOI: 10.1159/000553602 PMID: 42455743

The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.

Dubé LR, Sorin M, Allez M, Afif W, Bitton A, Lakatos PL, Wild G, Magro F, Patel A, Guardiola J, Bessissow T

Alimentary pharmacology & therapeutics2026

DOI: 10.1111/apt.70735 PMID: 42227157

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Niyigena E, Hoffert Y, Afif W, Pedicelli A, Roblin X, Hanžel J, Papamichael K, Kobayashi T, Elens L, Wang Z, Ferrante M, Verstockt B, Vermeire S, Vande Casteele N, Battat R, Dreesen E

Journal of Crohn's & colitis2026

DOI: 10.1093/ecco-jcc/jjag029 PMID: 41873130

Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.

Khalaf R, Fields M, Fields E, Tardio N, Afif W, Schneider R, Ben-Shoshan M

International archives of allergy and immunology2026

DOI: 10.1159/000552457 PMID: 42102009

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars

Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W

World Journal of Gastroenterology20262 citations

DOI: 10.3748/wjg.v32.i9.114580

Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)

Shahrokh DK, Vender RB, Lynde CW, Rao J, Afif W, Steinhart AH, Narula N, Sutton E, Thorne C, Bessette L

Rheumatology and Therapy20261 citations

DOI: 10.1007/s40744-026-00846-1

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti–Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry

Oketola B, Bernatsky S, Lukusa L, Moura CS, Neville A, Leung Y, Narula N, Afif W, Birck MG, Zezos P

Gastro Hep Advances2026

DOI: 10.1016/j.gastha.2025.100821

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial

Rosenfeld G, Narula N, Leung Y, Afif W, Williams A-J, Huang V, Singh H, McCurdy JD, Jairath V, Lam M

Gastroenterology2026

DOI: 10.1053/j.gastro.2026.06.006

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat

Co-investigatorCIHR2026Project Grant

Principal investigators: Sebastiani, Giada; Bessissow, Talat; Betel, Michael; Saeed, Sahar Z; Swain, Mark G; Williams, Astrid-Jane

Keywords: Biobank; Biological Sex; Diabetes; Inflammatory Bowel Disease; Liver Fibrosis; Obesity; Patient Reported Outcomes; Risk Score; Steatotic Liver Disease

$1,005,976

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$5,222,039

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$1,305,510

Risk of infections with tumour necrosis factor inhibitors (TNFi) in pregnant women and their offspring

Co-investigatorCIHR2019Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health

Principal investigators: Vinet, Evelyne

Keywords: Ankylosing Spondylitis; Chronic Inflammatory Diseases; Inflammatory Bowel Diseases; Pregnancy; Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Rotavirus Vaccine; Serious Infections; Tumour Necrosis Factor Inhibitors

$105,000

Risk of infections with tumour necrosis factor inhibitors (TNFi) in pregnant women and their offspring

Co-investigatorCIHR2019Project Grant

Principal investigators: Vinet, Evelyne

Keywords: Administrative Database; Ankylosing Spondylitis; Chronic Inflammatory Diseases; Inflammatory Bowel Diseases; Pregnancy; Psoriasis And Psoriatic Arthritis; Rheumatoid Arthritis; Rotavirus Vaccine; Serious Infections; Tumour Necrosis Factor Inhibitors (Tnfi)

$382,500

Enhancing CAN-AIM capacity to respond to drug safety and effectiveness queries

Principal investigatorCIHR2019DSEN team grants: MAGIC and CAN-AIM

Principal investigators: Bernatsky, Sasha R; Abrahamowicz, Michal M; Afif, Waqqas; Awadalla, Philip; Bérard, Anick; Buckeridge, David L; Hazlewood, Glen S; Hohl, Corinne M; Kowalec, Kaarina A; Moride, Yola; Moura, Cristiano S; Pilote, Louise; Tremlett, Helen L

Keywords: Comparative Effectiveness And Safety; Confounding Bias; Exposure Measurement Errors; Pharmacoepidemiology; Prospective Studies; Statistical Modelling

$2,550,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Waqqas Afif

Research

Latest papers

Latest funding

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response.

Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.

The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars

Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti–Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Risk of infections with tumour necrosis factor inhibitors (TNFi) in pregnant women and their offspring

Risk of infections with tumour necrosis factor inhibitors (TNFi) in pregnant women and their offspring

Enhancing CAN-AIM capacity to respond to drug safety and effectiveness queries

Frequent collaborators

Talat Bessissow

Alain Bitton

Remo Panaccione

John Kenneth Marshall

Reena Khanna

Neeraj Narula

Sasha Bernatsky

Sasha Bernatsky

Jennifer Jones

Christopher Ma

Harminder Singh

Harminder Singh

Paul Moayyedi

Paul Brassard

Grigorios Leontiadis

Erin Kennedy

Sanjay Murthy

Vipul Jairath

Amine Benmassaoud

Giada Sebastiani

Sharyle Fowler

Alan Barkun

Alan Barkun

Moshe Ben-Shoshan

Ted Xenodemetropoulos

Smita Luna Sudeshna Halder

Elham Rahme

Peter Lakatos

Dina El Demellawy

Yen-I Chen

Nauzer Forbes

Laura Targownik

Marylise Boutros

Elena Netchiporouk

Mark Sorin

Janie Coulombe

Alene Toulany

Madhukar Pai